Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

A new review in Engineering reveals that CRISPR technologies are revolutionizing regenerative medicine. Scientists from ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

Researchers from Tel Aviv University utilized CRISPR to cut a single gene from cancer cells of head and neck tumors—and ...

Bioengineering professor and The Grainger College of Engineering's Dean, Rashid Bashir, led a team of researchers in a project that's resulted in new technology that offers rapid, highly sensitive ...

The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $41.17, denoting a -1.84% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0 ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) fell 2.9% on Thursday after an insider sold shares in the company. The company traded as low as $42.78 and last traded at $42.22. 282,558 shares ...

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from ...